Prerpints.org logo
Preprint
Article

Lycopene Promotes Osteogenesis and Reduces Adipogenesis through Regulating FoxO1/PPARγ Signaling in OVX Rats and BMSCs

This version is not peer-reviewed.

Submitted:

03 April 2024

Posted:

03 April 2024

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract
Recent interest in preventing the development of osteoporosis has focused on the regulation of redox homeostasis. However, the action of lycopene (LYC), a strong natural antioxidant com-pound, on osteoporotic bone loss remains largely unknown. Here, we show that the administra-tion of LYC to OVX rats reduces body weight gain, improves lipid metabolism and preserves bone quality. In addition, LYC treatment inhibits ROS overgeneration in serum and bone marrow in OVX rats, and in BMSCs upon H2O2 stimulation, leading to inhibiting adipogenesis and pro-moting osteogenesis during bone remodeling. Mechanically, LYC may improve bone quality via an increase in the expressions of FoxO1 and Runx2, and a decrease in the expressions of PPARγ and C/EBPα in OVX rats and BMSCs. Collectively, these findings suggest that LYC attenuates osteoporotic bone loss through promoting osteogenesis and inhibiting adipogenesis via regula-tion of the FoxO1/PPARγ pathway driven by oxidative stress, presenting a novel strategy for os-teoporosis management.
Keywords: 
Subject: 
Biology and Life Sciences  -   Food Science and Technology

1. Introduction

Lycopene (LYC), one kind of dietary lipid-soluble carotenoids, mostly found in tomatoes and other fruits with red color[1], and is well known for its high antioxidant potential[2]. As a natural nutrient, LYC is appealing to scientists and clinicians’ interests for its great contribution to attenuating various disorders such as cancers[3,4], cardiovascular disease[5], aging[6], obesity and diabetes[7,8]. Interestingly, recent findings have suggested that LYC may improve bone quality and attenuate bone loss in obese and osteoporotic animals[9,10]. However, the underlying mechanisms of this compound on osteoporosis still need further investigation.
Osteoporosis is a kind of degenerative bone disease which characterized by skeletal fragility and microarchitectural deterioration, leading to an increased risk of fracture[11,12]. Epidemiological evidence suggests that the prevalence of osteoporosis has continuously increased over the past decades[13]. The consequent high risk of disability and mortality of this disease has become one of the major threats to life expectancy and quality in aging population[14], considering the undesired side effects and limitations of the current anti-osteoporotic medications[10,15]. Thusly, clinical trials are still waiting for the new countermeasures to the treatment of osteoporosis.
There is emerging evidence suggests that FoxO1 contributes to bone remodeling through regulation of oxidative stress[16,17]. Indeed, FoxO1 alleviates bone quality through promoting adipogenesis and suppressing osteogenesis via inhibition of PPARγ in bone marrow mesenchymal stem cells (BMSCs)[18,19]. In contrast, an increased expression of PPARγ triggered by oxidative stress may divert BMSCs from osteogenesis to adipogenesis[20], thusly contributing to the development of osteoporosis[21].
We have previously demonstrated that LYC prevented the development of osteoporosis in obese mouse[22]. In addition, we have also found that LYC improved lipid metabolism in obese mouse[23]. The evidence from clinical studies and preclinical trials suggest that LYC may have a beneficial role in the management of osteoporosis[24,25,26]. In the light of these findings, we hypothesize that LYC may improve bone remodeling through regulation of osteogenesis and adipogenesis to prevent the development of osteoporosis. For this purpose, ovariectomized (OVX) rats and BMSCs were used to investigate the actions and mechanisms of LYC on bone quality.

2. Materials and Methods

2.1. Materials

LYC was purchased from RuiFenSi Biotechnology Co., Ltd. (Chengdu, China). Alizarin Red S was purchased from Sigma-Aldrich (St. Louis, MO, USA). Antigen retrieval solution was bought from ShunBai Biotechnology Company (No: SBT10013; Shanghai, China). The kits for triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), total antioxidant capacity (T-AOC), superoxide dismutase (SOD), malondialdehyde (MDA) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). The ELISA kits, including N-terminal propeptide of type1 procollagen (P1NP; Cat#: MB-7402A) and C-terminal cross-linked telopeptide of type I collagen (CTX-1; Cat#: MB-7275A) were purchased from Jiangsu MeiBiao Biological Technology Co., Ltd. Antibodies against OCN (WLH4378) and Runx2 (WL03358) were bought from Wanlei Biotechnology (Shenyang, China). Antibodies against FoxO1 (18592-AP), PPARγ (16643-1-AP), C/EBPα (18311-1-AP), GAPDH (60004-1-Ig) and β-actin (66009-1-Ig) were from the Proteintech Biotechnology (Wuhan, China). HRP-conjugated goat anti-rabbit and anti-mouse secondary antibodies were procured from Proteintech Biotechnology. All other reagents, except specially identified, were from Sinopharm Reagents Co. Ltd. (Beijing, China).

2.2. BMSCs Culture

BMSCs were isolated and identified from the femurs and tibias of 80-100 g Sprague-Dawley (SD) rats according to the procedures provided in the previous publication[27]. Briefly, the rat was killed by cervical dislocation and immersed in 75% ethanol for about 10 min. Then, both the femurs and tibias were removed from the animal body. And the bone marrow was rinsed with DMEM/low glucose medium using a syringe. After centrifugation, the pellets were collected and cultured with DMEM/low glucose medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in a humidified incubator containing 5% CO2 at 37 °C. BMSCs less than 3 passages were used for the further experiments. For characterization of BMSCs, 5 × 106 BMSCs were collected and washed with PBS. Then the cells were incubated with PE-labeled anti-CD90 and APC-labeled anti-CD45 at 4 °C for 40 min, and subsequently subjected to flow cytometry assay.

2.3. Cell Viability Assay

BMSCs (1×104 cells) were cultured in a 96-well plate until approximately 70% confluence. Then, cells were treated with various concentrations of LYC (1-10 μM) for 24, 48 and 72 h, respectively. Subsequently, serum-free medium with 10% CCK8 was added to each well of the plate. And absorbance at 450 nm was measured using a FLUOstar Omega microplate reader (Ortenberg, Germany) after incubation 37 °C for 1 h. For each condition, six replicates were performed throughout the experiments.

2.4. Intracellular ROS Examination

ROS production was measured using a 2,7-dichlorofluorescein diacetate (DCFH-DA) fluorescent probe. For observation of DCF fluorescence, 1 × 104 BMSCs were seeded in 96-well black plates and cultured with DMEM/low glucose medium for 24 h. Then, the cells were cultured with LYC and/or osteogenic induction medium for 24 h. Subsequently, cells were treated with 200 μM H2O2 for 2 h and followed by incubation with 10 μM DCFH-DA at 37◦C for 20 min in the dark. Finally, cells were washed with serum-free medium. And the fluorescence intensity was measured under an automatic microplate reader.

2.5. Alizarin Red S Staining

Alizarin Red S staining was used to evaluate the osteogenesis in BMSCs and bone tissues. For BMSCs, the cells were incubated with or without LYC in the presence of osteogenic induction medium for 14 days, and subsequently treated with 200 μM H2O2 for 2 h. Then, cells were fixed with 95% ethanol for 10 min at room temperature followed by staining with Alizarin Red S solution (1 g of Alizarin Red in 100 ml of distilled water, pH 4.0-4.2) for 0.5 h in the dark. After staining, cells were washed with PBS and then photographed under a microscope.
For bone tissues, Alizarin Red S staining was performed according to the protocol as previously published[28]. After staining, the slides were observed and photographed using an Olympus BX53 fluorescence microscope (Tokyo, Japan). For the analysis, the relative interest of density of Alizarin red S staining was quantified using the Image Pro Plus 6.0 software.

2.6. Oil Red O (ORO) Staining

ORO staining was used to measure the lipids production in BMSCs. Briefly, after incubation with or without LYC in the presence of osteogenic induction medium for 14 days, BMSCs were treated with 200 μM H2O2 for 2 h, followed by fixation with 4% paraformaldehyde for 10 min at room temperature and staining with ORO solution [the stock solution (0.5 g of ORO in 100 ml of isopropanol) diluted with water (60:40, v/v)] for 0.5 h in the dark. After staining, cells were photographed under a microscope to examine the lipid production. And the relative interest of density of ORO staining was quantified using the Image Pro Plus 6.0 software.

2.7. Induction of Osteoporotic Models and LYC Administration

Fifty female SD rats (230 ± 10 g, 11 weeks of age) were purchased from Beijing Jinmuyang Experimental Animal Breeding Co. Ltd. [certification number SCXK 2016-0010] and housed in the clean level animal facilities at the Beijing University of Chinese Medicine (BUCM) with the temperature of 22°C ± 1°C, humidity of 55% ± 5% and a 12-h light/dark cycle. All the rats were allowed free access to tap water and chow. All the animal protocols were approved by the Animal Care Committee of BUCM, China.
After acclimation for 1 week, rats were anesthetized and ovariectomized by removing the bilateral ovaries to establish osteoporotic models according to the previous procedures[29]. In addition, sham-operated rats were subjected to similar operation by removing the equal volume of fats surrounding the ovaries [30].
One week after surgery, ovariectomized rats were randomly divided into 4 groups with 10 in each, namely the OVX, estradiol valerate (EV), high-dose LYC (LYCH) and low-dose LYC (LYCL) groups. Rats in the EV, LYCH and LYCL groups were orally administrated with estradiol valerate tablets (0.1 mg/ kg), and LYC (LYCH, 30 mg/ kg; LYCL, 15 mg/ kg) dissolved in sunflower oil, respectively. Rats in the OVX and SHAM groups were orally gavaged with the equal volume of the vehicle. During the treatment, body weight was recorded every week. After 12 weeks of intervention, serum was collected from abdominal aorta of anesthetized rats. Then, the uterus was removed and weighted. And the bilateral tibias and femurs were dissected from the animal body. The samples were then either stored at −80 °C or soaked in 10% neutral formalin for the further experiments.

2.8. Serum and Bone Marrow Biomarkers Analysis

Serum TG, TC, HDL, LDL, bone marrow TG and TC were detected using the corresponding commercial kits according to the manufacturer’s instructions. The levels of T-AOC, SOD and MDA were determined by biochemical assays. The serum levels of CTX-1 and P1NP were also measured using the corresponding ELISA kits according to the manufacture’s instruction.
2.9. μ-CT Scanning
The right femurs were subjected to the μ-CT scanning as previously described[31,32]. Briefly, the right femur was scanned and captured by the Quantum GX μCT instrument (PerkinElmer, USA). The parameters in the volume of interest were analyzed by the Analyzer Software (V12.0), including: (1) BMD (bone mineral density); (2) BV/TV (bone volume fraction); (3) BS/TV (bone surface density); (4) Tb.N (trabecular number); (5) Tb.Sp (trabecular separation); (6) Tb.Th (trabecular thickness); (7) Conn.D (connectivity density); (8) SMI (Structure Model Index).

2.10. Bone Biomechanical Strength Assay

After the μCT scanning, the right femurs were taken for a three-point bending assay by an electronic universal testing machine (Shimadzu Corporation, AGS-X500, Japan), as previously described[31,32]. The shaft of the femur was fixed between the two supporting points, with a distance of 20 mm. Then, a certain load was vertically administered to the tibial midshaft at the speed of 1 mm/min until the tibial shaft is fractured. The ultimate load, bending strength, and elastic modulus of the femurs were analyzed by an electronic universal testing apparatus.

2.11. Fourier Transform Infrared Spectroscopy (FTIR) Assay

After that, the rat femur was grinded to powder in a ceramic mortar. The spectrum was obtained by the FTIR (Bruker Vertex 70, Germany). Scanning was performed in transmission mode in the 4,000-400cm−1 range with accumulating 64 scans. The relative ratio of carbonate to phosphate, the area ratio v1, v3 band to v2 CO3 were determined as previously published[33,34].

2.12. Haematoxylin & Eosin (H&E) and Safranin O-Fast Green Staining

The left femurs of the rats were fixed with 10% neutral formalin and then decalcified in 10% neutral EDTA buffer for 3 months. Then, femurs were embedded in paraffin. Sections (5-µm) were subjected to the H&E staining and safranin O-fast green staining according to the routine protocols[28,35].

2.13. Immunohistochemistry (IHC) Staining

IHC staining was conducted according to the procedures provided in the previous publication[31]. Briefly, 5-μm section was incubated with appropriate primary antibody [OCN (1:1000), Runx2 (1:1000), PPARγ (1:1000) and FoxO1 (1:1000)], respectively, overnight at 4 ◦C. Subsequently, the section was incubated with the corresponding horseradish peroxidase-conjugated secondary antibody. Finally, the section was observed and photographed using an Olympus BX53 microscopy. The intensity of positive staining was analyzed using the Image Pro Plus6.0 software and expressed as IOD value.

2.14. Western Blot Assay

Proteins were obtained from the femurs and BMSCs, and determined using BCA assay kit. After that, the proteins were subjected to SDS-PAGE gel and transferred onto PVDF membranes. Then, the PVDF membranes were sequentially incubated with the appropriate primary antibody [Runx2 (1:1000), PPARγ (1:1,000), FoxO1 (1:1000), GAPDH (1:20,000), β-actin (1:5,000), and Lamin B1 (1:2,000), respectively, at 4°C overnight. The next day, after incubation with corresponding HRP-labeled secondary antibody for 1 h at room temperature, immune-positive bands were detected using high-sensitivity ECL and captured with Azure Bio-imaging systems. Gray values of the images were analyzed with Image J software and normalized with the same membrane of β-actin or Lamin B1 as the internal control.

2.15. Statistical Analysis

Data were analyzed by ANOVA or a nonparametric test according to the homogeneity of variance and normality (GraphPad Prism 9). The results were expressed as mean ± SD. p < 0.05 was regarded as a statistical difference.

3. Results

3.1. LYC Preserves Bone Micro-Architecture, Strength, Material Properties in OVX Rats

As shown in Figure 1A, H&E staining revealed that the trabecular bone in the distal femurs of the OVX group became thinner, irregular and appeared disorganized mesh structure compared with those in the SHAM group. In addition, the lipid droplets (indicated by the black arrow) were much more obvious in the proximal femurs of OVX group than those in the SHAM group. As expected, LYC or EV treatment obviously improved femoral histopathological architecture in OVX rats.
In order to further investigate the effect of LYC on the alterations of bone microstructure, the femurs were subjected to a μCT scanning. As shown in Figure 1B-J, the μCT images of the distal femoral showed that the trabecular bone microstructure was mostly destroyed, and exhibited a decrease in BMD, BV/TV, BS/TV, Tb.N, Tb.Th and Conn.D, and an increase in Tb.Sp and DA in the OVX group compared with those in the SHAM group. However, treatment of OVX rats with EV or LYC for 12 weeks markedly improved the trabecular bone microstructure and reversed the abovementioned parameters in OVX rats (p < 0.05).
Next, we analyzed bone biomechanical properties, including elastic modulus, bending strength and ultimate load in the femurs by three-point bending assay. As shown in Figure 1K-M, the elastic modulus, bending strength and ultimate load in the femurs of the OVX group were significantly lower than those in the SHAM one (p < 0.05). As expected, treatment of OVX rats with EV or LYC prevented a decline in the abovementioned parameters in the femurs (p < 0.05).
To further evaluate the effect of LYC on bone material quality, the femurs were subjected to the FTIR. As shown in Figure 1N, the relative ratios of carbonate to phosphate were significantly increased in the femurs of the OVX group compared with those in the SHAM one (p < 0.05). While treatment with EV or LYC obviously reversed the alteration in the femurs of OVX rats (p < 0.05). These results suggest that LYC has the ability of improving bone strength and microstructure as well as preserving bone material profiles in OVX rats.

3.2. LYC Inhibits Oxidative Stress in OVX Rats and in BMSCs

Inspired by the notion that LYC is a strong anti-oxidant product [36], we first investigated the effect of this compound on redox stress in OVX rats. As shown in Figure 2A-C, serum levels of T-AOC and SOD were decreased, and serum levels of MDA were increased, respectively, in the rats of the OVX group, relative to those in the SHAM group (p < 0.05). In addition, we further determined the levels of T-AOC and SOD in the bone marrow. As shown in Figure 2D and E, the levels of T-AOC and SOD were decreased in the OVX group, which were in line with serum redox status. As expected, supplement of LYC to OVX rats reversed the alterations of the abovementioned alterations in serum and bone marrow in comparison with those of the vehicle-treated ones (p < 0.05). These results suggest that LYC may alleviate oxidative stress in OVX rats.
In order to further investigate the actions of LYC on the primary BMSCs upon H2O2 stimulation, we first characterized BMSCs by flow cytometry. As shown in Figure 2F-G, BMSCs were characterized by a positive staining with CD90 and a negative staining for CD45, indicating that BMSCs were successfully isolated. Next, the effects of LYC on cell proliferation were detected by the CCK-8 assay. As shown in Figure 2H, 1 to 4 μM of LYC did not affect cell proliferation at 24 h and 48 h, indicating that LYC at these concentrations does not affect the cell viability.
After identification of the optimum condition for H2O2 exposure (200 μM, 1h; Figure 2I), the effects of LYC (0, 1, 2, 4, 8, and 10 μM) on H2O2-stimulated BMSCs were evaluated by the CCK-8 assay. As shown in Figure 2J, LYC at the levels of 2-10 μM could promote cell proliferation at 24, 48 and 72 h. Comprehensively considering the abovementioned findings, 2 and 4 μM of this compound were selected as the optimum concentration for the ensuing experiments.
Next, we examined whether LYC could attenuate H2O2-induced ROS production in BMSCs by DCFH-DA staining. As shown in Figure 2K, H2O2 stimulation induced a significant increase in the fluorescence intensity in BMSCs (p < 0.05). As expected, the addition of LYC (2 and 4 μM) to BMSCs significantly decreased fluorescence intensity relative to those of the vehicle treated (p < 0.05). These results demonstrated that LYC was capable of rebuilding redox homeostasis in BMSCs and OVX rats.

3.3. LYC Improves Lipid Metabolism in OVX Rats and BMSCs

As shown in Figure 3A, at the 12th week, the body weight of the rats in the OVX group was significantly greater than that in the SHAM group. However, compared to the OVX group, the body weight of the rats in the LYCL and LYCH groups was significantly decreased (p < 0.05). In addition, as shown in Figure 3B-E, the rats in the OVX group showed an obvious increase in serum levels of TG, TC, LDL and a significant decrease in serum levels of HDL relative to those in the SHAM group (p < 0.05). Interestingly, LYC (LYCL and LYCH) treatment reversed the abovementioned alterations in OVX rats (p < 0.05).
Next, we investigated the alterations of lipid profiles in the bone marrow. As shown in Figure 3F and G, the levels of TG and TC in the bone marrow of the OVX group were markedly increased relative to those in the SHAM group (p < 0.05). Similarly, LYC (LYCL and LYCH) treatment notably reversed the alterations in the bone marrow of OVX rats (p < 0.05). Additionally, as shown in Figure 3H and I, LYC administration significantly reduced the accumulation of lipid droplets in BMSCs under H2O2 stimulation (p < 0.05). These results suggest that LYC could improve lipid metabolism in OVX rats.

3.4. LYC Promotes Osteogenesis in OVX Rats and in BMSCs

It is well known that serum P1NP is an indicator of the synthesis of type I collagen, and positively correlated with the bone formation. And serum CTX-1 is a product of type I collagen degradation, and positively associated with the bone resorption[37]. As shown in Figure 4A&B, the results from the ELISA demonstrated that serum P1NP levels were significantly decreased and serum CTX-1 levels were significantly increased in the OVX group, respectively, when compared with those in the SHAM group (p < 0.05). However, after treatment with LYC (LYCL and LYCH) for 12 weeks, the alterations of serum P1NP and CTX-1 were notably reversed as compared to those in the OVX group (p < 0.05).
Glycosaminoglycans (GAGs) play a favorable role in bone remodeling through promotion of osteogenesis[38]. And Safranin O dye stains proteoglycans in cartilage to red. As shown in Figure 4C and D, GAGs levels were significantly reduced in the OVX group when compared to those in the SHAM group (p < 0.05). Not surprisingly, after treatment with LYC (LYCL and LYCH) for 12 weeks, GAGs levels were significantly increased when compared to those in the OVX group (p < 0.05).
Next, we examined the effect of LYC on osteogenesis in OVX rats. As shown in Figure 4E and F, the results from the Alizarin Red S staining (indicated by the blue pentagram), rats in the OVX group exhibited a decrease in the area of calcium nodules in the femurs (p < 0.05). Notably, LYC (LYCL and LYCH) treatment obviously improved the distribution and increased the areas of calcium nodules in the femurs as compared to those of the vehicle-treated OVX rats (p < 0.05). Additionally, LYCL is better than LYCH in attenuating bone histomophological disorders in the femurs of OVX rats (p < 0.05). Therefore, in the following experiments, LYCL was selected to further study the underlying mechanisms of this compound in prevention against osteoporosis.
Moreover, as shown in Figure 4G and H, H2O2 stimulation significantly reduced the formation of calcium nodules in BMSCs (p < 0.05). Interestingly, the addition of LYC (2 and 4 μM) obviously attenuated the limitation of calcium nodules formation in BMSCs upon H2O2 stimulation (p < 0.05). These findings indicate that LYC may attenuate bone loss through promoting bone formation and inhibiting bone resorption in OVX rats.

3.5. LYC Increases FoxO1, Runx2, and OCN Expressions, and Inhibits PPARγ and C/EBPα Expressions in the Femurs and Tibias of OVX Rats and BMSCs

As shown in Figure 5A-C, G-I and J-K, the results from IHC staining and/or western blots showed that the expressions of FoxO1, Runx2 and OCN in the femurs and tibias were notably decreased in the OVX group when compared to those in the SHAM group (p < 0.05). And LYC treatment significantly increased the expressions of FoxO1, Runx2 and OCN in the bones of OVX rats compared to those of the vehicle-treated (p < 0.05).
Moreover, as shown in Figure 5D-F and L, the expressions of PPARγ and C/EBPα were significantly increased in the femurs and tibias of the OVX group compared with those in the SHAM group as determined by IHC staining and/or western blots (p < 0.05). Intriguingly, LYC treatment markedly reduced the expressions of PPARγ and C/EBPα in the femurs and tibias of OVX rats (p < 0.05). These results suggest that LYC has the ability of promoting osteogenesis and suppressing adipogenesis in OVX rats.
In order to further elucidate the underlying mechanism, BMSCs were subjected to H2O2, LYC and/or AS1842856 (a FoxO1 inhibitor) stimulation. As shown in Figure 5M and N, the results from western blots showed that the expressions of FoxO1 and Runx2 were notably decreased in BMSCs upon H2O2 and AS1842856 stimulation when compared to those of the vehicle-treated ones (p < 0.05). Interestingly, LYC treatment significantly reversed the expressions of FoxO1 and Runx2 in BMSCs upon H2O2 and/or AS1842856 exposure (p < 0.05).
In addition, as shown in Figure 5O, the expression of PPARγ in BMSCs was significantly increased upon H2O2 and AS1842856 stimulation compared with those of the vehicle-treated (p < 0.05). Intriguingly, this alteration was reversed by LYC treatment (p < 0.05). These results suggest that LYC has the ability of promoting osteogenesis and suppressing adipogenesis through regulation of the FoxO1/PPARγ signaling in OVX rats.

4. Discussion

The disturbed redox homeostasis promotes adipogenesis and inhibits osteogenesis, thusly attenuating bone formation[39,40]. The countermeasures focusing on alleviating oxidative stress may offer a novel solution for preventing the development of osteoporosis[41,42,43]. In the present study, the following evidence was provided using OVX rats and BMSCs: (1) LYC improves bone microarchitecture, mechanical strength and material constituents; (2) LYC increases serum P1NP levels, calcium nodules and bone GAGs levels, and decreases serum CTX-1 levels; (3) LYC decreases serum and/or bone marrow TC, TG, and LDL, increases serum HDL levels, and inhibits lipid droplets formation; (4) LYC attenuates ROS production and increases serum and bone marrow of T-AOC and SOD levels, and decreases serum MDA levels; (5) LYC increases the expression levels of FoxO1, OCN and Runx2, and decreases the expression levels of PPARγ and C/EBPα.
In the current study, LYC is demonstrated to reduce body weight gain and improve serum lipid metabolism, which is in line with the previous investigations[44,45]. In addition, we found that LYC is able to reduce lipid formation and improve lipid profiles in bone marrow. Moreover, LYC was reported to reduce lipogenesis in BMSCs[46]. As is known that osteoporosis may coexist with dyslipidemia in postmenopausal women[47,48]. And LYC were found to improve blood lipoprotein in postmenopausal women[48]. Thusly, these findings suggest that LYC may ameliorate lipid metabolism to improve bone quality in OVX rats.
In the present study, we found that LYC treatment did ameliorate bone quality evidenced by an improvement of bone microstructure, mechanical strength and material profiles in OVX rats. This is in agreement with the previous investigations[49,50,51]. Our group also found that LYC improves bone quality in obese mouse[22]. Clinically, LYC was reported to prevent osteoporotic bone loss in postmenopausal women[10,52]. Therefore, these results suggest that LYC has an ability to improve bone quality in osteoporotic patient, which may provide a novel strategy for the management of this prevalent degenerative bone disease.
In the current study, we firstly showed that LYC promotes osteogenesis in OVX rats by increasing GAGs contents and promoting calcium nodules formation in the femurs. Then, we found that LYC could attenuate the limitation of osteogenesis in BMSCs upon H2O2 stimulation. Likewise, LYC was reported to promote osteogenesis in OVX rats[50,51], BMSCs[53] and osteoporotic women[52]. Collectively, these results indicate LYC may prevent the development of osteoporosis through promoting osteogenesis.
LYC is found to restore redox homeostasis by increasing serum and bone marrow levels of anti-oxidant markers (SOD and T-AOC), and decreasing serum levels of oxidant markers (MDA). In addition, LYC is demonstrated to reduce ROS production (DCFH-DA assay) in BMSCs upon H2O2 stimulation. Along this line, Iimura et al.[54] reported that LYC intervention could inhibit bone loss by reducing oxidative stress in OVX rats. The evidence from clinical studies also showed that LYC is able to decrease oxidative stress and inhibit bone resorption in postmenopausal women[26,55]. Together, our current findings in conjunction with the abovementioned findings from other groups suggest that LYC may prevent the development of osteoporosis through inhibition of oxidative stress overproduction.
The present study demonstrated an increase in the expressions of FoxO1, Runx2 and OCN, and a decrease in the expressions of PPARγ and C/EBPα in the femurs and tibias of OVX rats in response to LYC treatment. These alterations were also demonstrated in BMSCs upon H2O2 stimulation. Similarly, LYC was reported to attenuate oxidative stress through upregulation of FoxO1 expression in mouse exposure to atrazine[56,57]. Additionally, LYC was reported to inhibit ROS overproduction and PPARγ expression in the hearts, kidneys and livers of the rats on high-fat or high-cholesterol diet[58,59]. Liao et.al also reported that FoxO1 deficiency may promote bone loss through increasing ROS overproduction[60]. FoxO1 could facilitate osteoblasts differentiation and mannerization by inhibiting oxidative stress[61]. Moreover, FoxO1 may bind with the PPARγ promoter to inhibit the transcriptional activity of PPARγ, thusly limiting the adipose differentiation[62,63]. Furthermore, a recent study reported by Ardawi et al. suggested that LYC promoted osteogenesis and inhibited adipogenesis in rat BMSCs[53]. Here, we also demonstrated that LYC increases calcium nodule formation and decreases lipid droplets formation in BMSCs and OVX rats. Using a FoxO1 inhibitor, we found that the actions of LYC on osteogenesis and adipogenesis was associated with the FoxO1 and PPARγ. Taken together, these findings indicate that LYC might promote osteogenesis and reduce adipogenesis through regulating redox homeostasis via the FoxO1/PPARγ signaling pathway in OVX rats.
Some limitations still existed in the present study when interpreting the data. Firstly, we did not employ FoxO1 deficient mouse to investigate the action of LYC on bone quality. However, FoxO1 was reported to be positively involved in promotion of osteogenesis and inhibition of adipogenesis in OVX animals[64,65] and in BMSCs[66]. LYC was able to attenuate oxidative stress via increasing FoxO1 expression in mouse exposed to atrazine[56]. Secondly, we did not study the direct effect of LYC on PPARγ expression in BMSCs. However, we employ a FoxO1 inhibitor to show that LYC could inhibit PPARγ expression in BMSCs upon H2O2 stimulation. In addition, LYC was reported to inhibit PPARγ expression in hypercholesterolemic and obese rats[58,59].

5. Conclusions

In summary, LYC may attenuate bone loss through promotion of osteogenesis and inhibition of adipogenesis via regulation of redox homeostasis in OVX rats. The underlying mechanism behind these alterations may be related to the action of this compound on the FoxO1/PPARγ signaling. These results suggest that dietary consumption of LYC may offer a novel therapeutic strategy for the treatment of osteoporosis, which needs to be further identified in clinical trials.

Author Contributions

BX, XD, LW, RZ and DZ: Conceptualization, Methodology, Software. BX, XD, HS, JY, TX, TL: Data curation, Writing-Original draft preparation. BX, XD, GY, HG, RL, XC, YL: Visualization, Investigation. JG, XW, LW and DZ: Supervision. BX, XD, HS, JY, JT and RZ: Software, Validation. BX, XD, RZ, LW and DZ: Writing-Reviewing and Editing.

Funding

This research was funded by the National Natural Science Foundation of China (Nos. 82074235, 81874373 and 82274335).

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Review Board (or Ethics Committee) of the Animal Care Committee of BUCM, China (protocol code: BUCM-4-2019061701-3001; date of approval: 2019.6).

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors on request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Costa-Rodrigues, J.; Fernandes, M.H.; Pinho, O.; Monteiro, P.R.R. Modulation of Human Osteoclastogenesis and Osteoblastogenesis by Lycopene. J Nutr Biochem 2018, 57, 26–34. [Google Scholar] [CrossRef]
  2. Grabowska, M.; Wawrzyniak, D.; Rolle, K.; Chomczyński, P.; Oziewicz, S.; Jurga, S.; Barciszewski, J. Let Food Be Your Medicine: Nutraceutical Properties of Lycopene. Food Funct 2019, 10, 3090–3102. [Google Scholar] [CrossRef]
  3. Terao, J. Revisiting Carotenoids as Dietary Antioxidants for Human Health and Disease Prevention. Food Funct 2023, 14, 7799–7824. [Google Scholar] [CrossRef]
  4. Ozkan, G.; Günal-Köroğlu, D.; Karadag, A.; Capanoglu, E.; Cardoso, S.M.; Al-Omari, B.; Calina, D.; Sharifi-Rad, J.; Cho, W.C. A Mechanistic Updated Overview on Lycopene as Potential Anticancer Agent. Biomed Pharmacother 2023, 161, 114428. [Google Scholar] [CrossRef]
  5. Kulawik, A.; Cielecka-Piontek, J.; Zalewski, P. The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene. Nutrients 2023, 15, 3821. [Google Scholar] [CrossRef]
  6. Abir, M.H.; Mahamud, A.G.M.S.U.; Tonny, S.H.; Anu, M.S.; Hossain, K.H.S.; Protic, I.A.; Khan, M.S.U.; Baroi, A.; Moni, A.; Uddin, M.J. Pharmacological Potentials of Lycopene against Aging and Aging-Related Disorders: A Review. Food Sci Nutr 2023, 11, 5701–5735. [Google Scholar] [CrossRef]
  7. Zhu, R.; Chen, B.; Bai, Y.; Miao, T.; Rui, L.; Zhang, H.; Xia, B.; Li, Y.; Gao, S.; Wang, X.-D.; et al. Lycopene in Protection against Obesity and Diabetes: A Mechanistic Review. Pharmacol Res 2020, 159, 104966. [Google Scholar] [CrossRef]
  8. Saini, R.K.; Prasad, P.; Lokesh, V.; Shang, X.; Shin, J.; Keum, Y.-S.; Lee, J.-H. Carotenoids: Dietary Sources, Extraction, Encapsulation, Bioavailability, and Health Benefits-A Review of Recent Advancements. Antioxidants (Basel) 2022, 11, 795. [Google Scholar] [CrossRef] [PubMed]
  9. Marcucci, G.; Domazetovic, V.; Nediani, C.; Ruzzolini, J.; Favre, C.; Brandi, M.L. Oxidative Stress and Natural Antioxidants in Osteoporosis: Novel Preventive and Therapeutic Approaches. Antioxidants (Basel) 2023, 12, 373. [Google Scholar] [CrossRef] [PubMed]
  10. Walallawita, U.S.; Wolber, F.M.; Ziv-Gal, A.; Kruger, M.C.; Heyes, J.A. Potential Role of Lycopene in the Prevention of Postmenopausal Bone Loss: Evidence from Molecular to Clinical Studies. Int J Mol Sci 2020, 21, 7119. [Google Scholar] [CrossRef] [PubMed]
  11. Black, D.M.; Rosen, C.J. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 2016, 374, 254–262. [Google Scholar] [CrossRef]
  12. Ensrud, K.E.; Crandall, C.J. Osteoporosis. Ann Intern Med 2017, 167, ITC17–ITC32. [Google Scholar] [CrossRef]
  13. Salari, N.; Ghasemi, H.; Mohammadi, L.; Behzadi, M.H.; Rabieenia, E.; Shohaimi, S.; Mohammadi, M. The Global Prevalence of Osteoporosis in the World: A Comprehensive Systematic Review and Meta-Analysis. J Orthop Surg Res 2021, 16, 609. [Google Scholar] [CrossRef]
  14. Salari, N.; Darvishi, N.; Bartina, Y.; Larti, M.; Kiaei, A.; Hemmati, M.; Shohaimi, S.; Mohammadi, M. Global Prevalence of Osteoporosis among the World Older Adults: A Comprehensive Systematic Review and Meta-Analysis. J Orthop Surg Res 2021, 16, 669. [Google Scholar] [CrossRef]
  15. Lu, J.; Hu, D.; Ma, C.; Shuai, B. Advances in Our Understanding of the Mechanism of Action of Drugs (Including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis. Front Pharmacol 2022, 13, 938447. [Google Scholar] [CrossRef]
  16. Rached, M.-T.; Kode, A.; Xu, L.; Yoshikawa, Y.; Paik, J.-H.; Depinho, R.A.; Kousteni, S. FoxO1 Is a Positive Regulator of Bone Formation by Favoring Protein Synthesis and Resistance to Oxidative Stress in Osteoblasts. Cell Metab 2010, 11, 147–160. [Google Scholar] [CrossRef]
  17. Kousteni, S. FoxOs: Unifying Links between Oxidative Stress and Skeletal Homeostasis. Curr Osteoporos Rep 2011, 9, 60–66. [Google Scholar] [CrossRef]
  18. Ma, X.; Su, P.; Yin, C.; Lin, X.; Wang, X.; Gao, Y.; Patil, S.; War, A.R.; Qadir, A.; Tian, Y.; et al. The Roles of FoxO Transcription Factors in Regulation of Bone Cells Function. Int J Mol Sci 2020, 21, 692. [Google Scholar] [CrossRef]
  19. Li, Y.; Jin, D.; Xie, W.; Wen, L.; Chen, W.; Xu, J.; Ding, J.; Ren, D. PPAR-γ and Wnt Regulate the Differentiation of MSCs into Adipocytes and Osteoblasts Respectively. Curr Stem Cell Res Ther 2018, 13, 185–192. [Google Scholar] [CrossRef]
  20. Almeida, M.; Ambrogini, E.; Han, L.; Manolagas, S.C.; Jilka, R.L. Increased Lipid Oxidation Causes Oxidative Stress, Increased Peroxisome Proliferator-Activated Receptor-Gamma Expression, and Diminished pro-Osteogenic Wnt Signaling in the Skeleton. J Biol Chem 2009, 284, 27438–27448. [Google Scholar] [CrossRef]
  21. Kim, M.; Kim, C.; Choi, Y.S.; Kim, M.; Park, C.; Suh, Y. Age-Related Alterations in Mesenchymal Stem Cells Related to Shift in Differentiation from Osteogenic to Adipogenic Potential: Implication to Age-Associated Bone Diseases and Defects. Mech Ageing Dev 2012, 133, 215–225. [Google Scholar] [CrossRef] [PubMed]
  22. Xia, B.; Zhu, R.; Zhang, H.; Chen, B.; Liu, Y.; Dai, X.; Ye, Z.; Zhao, D.; Mo, F.; Gao, S.; et al. Lycopene Improves Bone Quality and Regulates AGE/RAGE/NF-кB Signaling Pathway in High-Fat Diet-Induced Obese Mice. Oxid Med Cell Longev 2022, 2022, 3697067. [Google Scholar] [CrossRef] [PubMed]
  23. Wang, J.; Suo, Y.; Zhang, J.; Zou, Q.; Tan, X.; Yuan, T.; Liu, Z.; Liu, X. Lycopene Supplementation Attenuates Western Diet-Induced Body Weight Gain through Increasing the Expressions of Thermogenic/Mitochondrial Functional Genes and Improving Insulin Resistance in the Adipose Tissue of Obese Mice. J Nutr Biochem 2019, 69, 63–72. [Google Scholar] [CrossRef] [PubMed]
  24. Yang, Z.; Zhang, Z.; Penniston, K.L.; Binkley, N.; Tanumihardjo, S.A. Serum Carotenoid Concentrations in Postmenopausal Women from the United States with and without Osteoporosis. Int J Vitam Nutr Res 2008, 78, 105–111. [Google Scholar] [CrossRef] [PubMed]
  25. Shen, C.-L.; von Bergen, V.; Chyu, M.-C.; Jenkins, M.R.; Mo, H.; Chen, C.-H.; Kwun, I.-S. Fruits and Dietary Phytochemicals in Bone Protection. Nutr Res 2012, 32, 897–910. [Google Scholar] [CrossRef] [PubMed]
  26. Rao, L.G.; Mackinnon, E.S.; Josse, R.G.; Murray, T.M.; Strauss, A.; Rao, A.V. Lycopene Consumption Decreases Oxidative Stress and Bone Resorption Markers in Postmenopausal Women. Osteoporos Int 2007, 18, 109–115. [Google Scholar] [CrossRef] [PubMed]
  27. Li, Y.; He, Y.; Chen, G.; Huang, Z.; Yi, C.; Zhang, X.; Deng, F.; Yu, D. Selenomethionine Protects Oxidative-Stress-Damaged Bone-Marrow-Derived Mesenchymal Stem Cells via an Antioxidant Effect and the PTEN/PI3K/AKT Pathway. Exp Cell Res 2021, 408, 112864. [Google Scholar] [CrossRef] [PubMed]
  28. Guo, Y.; Wang, L.; Ma, R.; Mu, Q.; Yu, N.; Zhang, Y.; Tang, Y.; Li, Y.; Jiang, G.; Zhao, D.; et al. JiangTang XiaoKe Granule Attenuates Cathepsin K Expression and Improves IGF-1 Expression in the Bone of High Fat Diet Induced KK-Ay Diabetic Mice. Life Sci 2016, 148, 24–30. [Google Scholar] [CrossRef] [PubMed]
  29. Chen, B.; Wang, L.; Li, L.; Zhu, R.; Liu, H.; Liu, C.; Ma, R.; Jia, Q.; Zhao, D.; Niu, J.; et al. Fructus Ligustri Lucidi in Osteoporosis: A Review of Its Pharmacology, Phytochemistry, Pharmacokinetics and Safety. Molecules 2017, 22, 1469. [Google Scholar] [CrossRef]
  30. Olfer’ev, A.M.; Il’ina, M.V.; Berzak, N.V.; Stetsenko, A.V.; Olfer’ev, M.A.; Chudakova, I.A.; Kapitanov, A.B.; Shamarin, V.M. [Effect of lycopene on blood lipoproteids in women with type 2 diabetes mellitus in postmenopause]. Vopr Pitan 2004, 73, 19–23. [Google Scholar]
  31. Li, L.; Chen, B.; Zhu, R.; Li, R.; Tian, Y.; Liu, C.; Jia, Q.; Wang, L.; Tang, J.; Zhao, D.; et al. Fructus Ligustri Lucidi Preserves Bone Quality through the Regulation of Gut Microbiota Diversity, Oxidative Stress, TMAO and Sirt6 Levels in Aging Mice. Aging (Albany NY) 2019, 11, 9348–9368. [Google Scholar] [CrossRef] [PubMed]
  32. Chen, B.; Wei, J.; Zhu, R.; Zhang, H.; Xia, B.; Liu, Y.; Dai, X.; Ye, Z.; Tian, Y.; Li, R.; et al. Fructus Ligustri Lucidi Aqueous Extract Promotes Calcium Balance and Short-Chain Fatty Acids Production in Ovariectomized Rats. J Ethnopharmacol 2021, 279, 114348. [Google Scholar] [CrossRef] [PubMed]
  33. Ou-Yang, H.; Paschalis, E.P.; Mayo, W.E.; Boskey, A.L.; Mendelsohn, R. Infrared Microscopic Imaging of Bone: Spatial Distribution of CO3(2-). J Bone Miner Res 2001, 16, 893–900. [Google Scholar] [CrossRef] [PubMed]
  34. Taylor, E.A.; Lloyd, A.A.; Salazar-Lara, C.; Donnelly, E. Raman and Fourier Transform Infrared (FT-IR) Mineral to Matrix Ratios Correlate with Physical Chemical Properties of Model Compounds and Native Bone Tissue. Appl Spectrosc 2017, 71, 2404–2410. [Google Scholar] [CrossRef] [PubMed]
  35. Zhu, C.-T.; Li, T.; Zhang, P.; Zou, M.; Guo, Q.; Qu, X.-W. Beneficial Effects of Low-Level Laser Irradiation on Senile Osteoporosis in Rats. Eur Rev Med Pharmacol Sci 2017, 21, 5230–5238. [Google Scholar] [CrossRef] [PubMed]
  36. Khan, U.M.; Sevindik, M.; Zarrabi, A.; Nami, M.; Ozdemir, B.; Kaplan, D.N.; Selamoglu, Z.; Hasan, M.; Kumar, M.; Alshehri, M.M.; et al. Lycopene: Food Sources, Biological Activities, and Human Health Benefits. Oxid Med Cell Longev 2021, 2021, 2713511. [Google Scholar] [CrossRef] [PubMed]
  37. Williams, C.; Sapra, A. Osteoporosis Markers. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2024. [Google Scholar]
  38. Zhu, H.; Wang, M.; Zhao, C.; Li, R.; Yang, J.; Pei, G.; Ye, T.; Zuo, X.; Liu, L.; Chong Lee Shin, O.L.; et al. GAG and Collagen II Attenuate Glucocorticoid-Induced Osteoporosis by Regulating NF-κB and MAPK Signaling. Am J Transl Res 2018, 10, 1762–1772. [Google Scholar] [PubMed]
  39. Iantomasi, T.; Romagnoli, C.; Palmini, G.; Donati, S.; Falsetti, I.; Miglietta, F.; Aurilia, C.; Marini, F.; Giusti, F.; Brandi, M.L. Oxidative Stress and Inflammation in Osteoporosis: Molecular Mechanisms Involved and the Relationship with microRNAs. Int J Mol Sci 2023, 24, 3772. [Google Scholar] [CrossRef] [PubMed]
  40. Lin, T.; Zhang, Z.; Wu, J.; Jiang, H.; Wang, C.; Ma, J.; Yin, Y.; Wang, S.; Gao, R.; Zhou, X. A ROS/GAS5/SIRT1 Reinforcing Feedback Promotes Oxidative Stress-Induced Adipogenesis in Bone Marrow-Derived Mesenchymal Stem Cells during Osteoporosis. Int Immunopharmacol 2023, 114, 109560. [Google Scholar] [CrossRef]
  41. Wang, Y.-F.; Chang, Y.-Y.; Zhang, X.-M.; Gao, M.-T.; Zhang, Q.-L.; Li, X.; Zhang, L.; Yao, W.-F. Salidroside Protects against Osteoporosis in Ovariectomized Rats by Inhibiting Oxidative Stress and Promoting Osteogenesis via Nrf2 Activation. Phytomedicine 2022, 99, 154020. [Google Scholar] [CrossRef]
  42. Lee, G.-H.; Hoang, T.-H.; Lee, H.-Y.; Lim, Y.-J.; Kim, J.-H.; Jung, S.-J.; Chae, S.-W.; Rashid, M.M.U.; Chae, H.-J.; Yoon, S.-J. Ramie Leaf Extract Alleviates Bone Loss in Ovariectomized Rats-The Involvement of ROS and Its Associated Signalings. Nutrients 2023, 15, 745. [Google Scholar] [CrossRef] [PubMed]
  43. Zhang, J.; Liu, S.; He, Z.; Liu, H.; Liu, Y.; Hu, P.; Li, Z.; Xu, J.; Luo, E. Adiponectin Overexpression Promotes Fracture Healing through Regulating the Osteogenesis and Adipogenesis Balance in Osteoporotic Mice. J Bone Miner Metab 2023, 41, 457–469. [Google Scholar] [CrossRef] [PubMed]
  44. Zhu, R.; Wei, J.; Liu, H.; Liu, C.; Wang, L.; Chen, B.; Li, L.; Jia, Q.; Tian, Y.; Li, R.; et al. Lycopene Attenuates Body Weight Gain through Induction of Browning via Regulation of Peroxisome Proliferator-Activated Receptor γ in High-Fat Diet-Induced Obese Mice. J Nutr Biochem 2020, 78, 108335. [Google Scholar] [CrossRef] [PubMed]
  45. Ardawi, M.-S.M.; Badawoud, M.H.; Hassan, S.M.; Rouzi, A.A.; Ardawi, J.M.S.; AlNosani, N.M.; Qari, M.H.; Mousa, S.A. Lycopene Treatment against Loss of Bone Mass, Microarchitecture and Strength in Relation to Regulatory Mechanisms in a Postmenopausal Osteoporosis Model. Bone 2016, 83, 127–140. [Google Scholar] [CrossRef] [PubMed]
  46. Tsartsalis, A.N.; Dokos, C.; Kaiafa, G.D.; Tsartsalis, D.N.; Kattamis, A.; Hatzitolios, A.I.; Savopoulos, C.G. Statins, Bone Formation and Osteoporosis: Hope or Hype? Hormones (Athens) 2012, 11, 126–139. [Google Scholar] [CrossRef] [PubMed]
  47. Yoshida, T.; Takahashi, K.; Yamatani, H.; Takata, K.; Kurachi, H. Impact of Surgical Menopause on Lipid and Bone Metabolism. Climacteric 2011, 14, 445–452. [Google Scholar] [CrossRef] [PubMed]
  48. Polyzos, S.A.; Anastasilakis, A.D.; Efstathiadou, Z.A.; Yavropoulou, M.P.; Makras, P. Postmenopausal Osteoporosis Coexisting with Other Metabolic Diseases: Treatment Considerations. Maturitas 2021, 147, 19–25. [Google Scholar] [CrossRef] [PubMed]
  49. Ricardo, V.; Sousa, L.G. de; Regalo, I.H.; Pitol, D.L.; Bombonato-Prado, K.F.; Regalo, S.C.H.; Siessere, S. Lycopene Enhances Bone Neoformation in Calvaria Bone Defects of Ovariectomized Rats. Braz Dent J 2023, 34, 50–56. [Google Scholar] [CrossRef] [PubMed]
  50. Semeghini, M.S.; Scalize, P.H.; Coelho, M.C.; Fernandes, R.R.; Pitol, D.L.; Tavares, M.S.; de Sousa, L.G.; Coppi, A.A.; Siessere, S.; Bombonato-Prado, K.F. Lycopene Prevents Bone Loss in Ovariectomized Rats and Increases the Number of Osteocytes and Osteoblasts. J Anat 2022, 241, 729–740. [Google Scholar] [CrossRef]
  51. Oliveira, G.R.; Vargas-Sanchez, P.K.; Fernandes, R.R.; Ricoldi, M.S.T.; Semeghini, M.S.; Pitol, D.L.; de Sousa, L.G.; Siessere, S.; Bombonato-Prado, K.F. Lycopene Influences Osteoblast Functional Activity and Prevents Femur Bone Loss in Female Rats Submitted to an Experimental Model of Osteoporosis. J Bone Miner Metab 2019, 37, 658–667. [Google Scholar] [CrossRef]
  52. Russo, C.; Ferro, Y.; Maurotti, S.; Salvati, M.A.; Mazza, E.; Pujia, R.; Terracciano, R.; Maggisano, G.; Mare, R.; Giannini, S.; et al. Lycopene and Bone: An in Vitro Investigation and a Pilot Prospective Clinical Study. J Transl Med 2020, 18, 43. [Google Scholar] [CrossRef] [PubMed]
  53. Ardawi, M.S.M.; Badawoud, M.H.; Hassan, S.M.; Ardawi, A.M.S.; Rouzi, A.A.; Qari, M.H.; Mousa, S.A. Lycopene Nanoparticles Promotes Osteoblastogenesis and Inhibits Adipogenesis of Rat Bone Marrow Mesenchymal Stem Cells. Eur Rev Med Pharmacol Sci 2021, 25, 6894–6907. [Google Scholar] [CrossRef]
  54. Iimura, Y.; Agata, U.; Takeda, S.; Kobayashi, Y.; Yoshida, S.; Ezawa, I.; Omi, N. The Protective Effect of Lycopene Intake on Bone Loss in Ovariectomized Rats. J Bone Miner Metab 2015, 33, 270–278. [Google Scholar] [CrossRef]
  55. Mackinnon, E.S.; Rao, A.V.; Josse, R.G.; Rao, L.G. Supplementation with the Antioxidant Lycopene Significantly Decreases Oxidative Stress Parameters and the Bone Resorption Marker N-Telopeptide of Type I Collagen in Postmenopausal Women. Osteoporos Int 2011, 22, 1091–1101. [Google Scholar] [CrossRef]
  56. Zhu, S.-Y.; Li, X.-N.; Zhao, Y.; Dai, X.-Y.; Guo, J.-Y.; Li, J.-L. Lycopene Ameliorate Atrazine-Induced Oxidative Damage in the B Cell Zone via Targeting the miR-27a-3p/Foxo1 Axis. J Agric Food Chem 2022, 70, 12502–12512. [Google Scholar] [CrossRef] [PubMed]
  57. Zhu, S.-Y.; Li, C.-X.; Tong, Y.-X.; Xu, Y.-R.; Wang, Z.-Y.; Li, J.-L. IL-6/STAT3/Foxo1 Axis as a Target of Lycopene Ameliorates the Atrazine-Induced Thymic Mitophagy and Pyroptosis Cross-Talk. Food Funct 2022, 13, 8871–8879. [Google Scholar] [CrossRef] [PubMed]
  58. Albrahim, T. Lycopene Modulates Oxidative Stress and Inflammation in Hypercholesterolemic Rats. Pharmaceuticals (Basel) 2022, 15, 1420. [Google Scholar] [CrossRef] [PubMed]
  59. Cao, C.; Sun, S.; Li, J.; Song, C.; Meng, Q.; Shi, B.; Shan, A. Lycopene Modulates Lipid Metabolism in Rats and Their Offspring under a High-Fat Diet. Food Funct 2021, 12, 8960–8975. [Google Scholar] [CrossRef]
  60. Liao, L.; Su, X.; Yang, X.; Hu, C.; Li, B.; Lv, Y.; Shuai, Y.; Jing, H.; Deng, Z.; Jin, Y. TNF-α Inhibits FoxO1 by Upregulating miR-705 to Aggravate Oxidative Damage in Bone Marrow-Derived Mesenchymal Stem Cells during Osteoporosis. Stem Cells 2016, 34, 1054–1067. [Google Scholar] [CrossRef]
  61. Zhang, Y.; Xiong, Y.; Zhou, J.; Xin, N.; Zhu, Z.; Wu, Y. FoxO1 Expression in Osteoblasts Modulates Bone Formation through Resistance to Oxidative Stress in Mice. Biochem Biophys Res Commun 2018, 503, 1401–1408. [Google Scholar] [CrossRef]
  62. Chen, J.; Lu, Y.; Tian, M.; Huang, Q. Molecular Mechanisms of FOXO1 in Adipocyte Differentiation. J Mol Endocrinol 2019, 62, R239–R253. [Google Scholar] [CrossRef] [PubMed]
  63. Kousteni, S. FoxO1, the Transcriptional Chief of Staff of Energy Metabolism. Bone 2012, 50, 437–443. [Google Scholar] [CrossRef] [PubMed]
  64. Xiao, H.-H.; Zhu, Y.-X.; Lu, L.; Zhou, L.-P.; Poon, C.C.-W.; Chan, C.-O.; Wang, L.-J.; Cao, S.; Yu, W.-X.; Wong, K.-Y.; et al. The Lignan-Rich Fraction from Sambucus Williamsii Hance Exerts Bone Protective Effects via Altering Circulating Serotonin and Gut Microbiota in Rats. Nutrients 2022, 14, 4718. [Google Scholar] [CrossRef] [PubMed]
  65. Jiang, Y.; Luo, W.; Wang, B.; Wang, X.; Gong, P.; Xiong, Y. Resveratrol Promotes Osteogenesis via Activating SIRT1/FoxO1 Pathway in Osteoporosis Mice. Life Sci 2020, 246, 117422. [Google Scholar] [CrossRef]
  66. Chen, P.; Hu, B.; Xie, L.-Q.; Jiang, T.-J.; Xia, Z.-Y.; Peng, H. Scara3 Regulates Bone Marrow Mesenchymal Stem Cell Fate Switch between Osteoblasts and Adipocytes by Promoting Foxo1. Cell Prolif 2021, 54, e13095. [Google Scholar] [CrossRef]
Preprints 102987 g001
Figure 1. Lycopene preserves bone micro-architecture, strength, material properties in OVX rats. Representative images of H&E (A) and μCT scanning (B) in the femurs of the different groups of rats. The BMD (C), BV/TV (D), BS/TV (1/mm) (E), Tb.N (1/mm) (F), Tb.Th (mm) (G), Tb.Sp (mm) (H), Conn.D (1/mm2) (I), and DA (J) in the femoral metaphysis were analyzed by the Analyzer Software. Elastic Modulus/d (K), Bending strength/d (L), Ultimate Load/d (M), and carbonate to phosphate (N) were determined by a three-point bending assay and Fourier-Transform Infrared Spectroscopy (FTIR), respectively. Data are presented as mean ± SD. Black arrow in panel (A) denotes lipid droplet. SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, EV denotes the estradiol group, LYCH denotes the high-dose lycopene group, LYCL denotes the low-dose lycopene group. # vs the SHAM group, * vs the OVX group. p < 0.05 was considered statistically significant.
Figure 1. Lycopene preserves bone micro-architecture, strength, material properties in OVX rats. Representative images of H&E (A) and μCT scanning (B) in the femurs of the different groups of rats. The BMD (C), BV/TV (D), BS/TV (1/mm) (E), Tb.N (1/mm) (F), Tb.Th (mm) (G), Tb.Sp (mm) (H), Conn.D (1/mm2) (I), and DA (J) in the femoral metaphysis were analyzed by the Analyzer Software. Elastic Modulus/d (K), Bending strength/d (L), Ultimate Load/d (M), and carbonate to phosphate (N) were determined by a three-point bending assay and Fourier-Transform Infrared Spectroscopy (FTIR), respectively. Data are presented as mean ± SD. Black arrow in panel (A) denotes lipid droplet. SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, EV denotes the estradiol group, LYCH denotes the high-dose lycopene group, LYCL denotes the low-dose lycopene group. # vs the SHAM group, * vs the OVX group. p < 0.05 was considered statistically significant.
Preprints 102987 g001
Preprints 102987 g002
Figure 2. Lycopene inhibits oxidative stress in OVX rats and in BMSCs. Serum and bone marrow levels of oxidative stress markers were determined by biochemical assays, including serum total antioxidant capacity (Serum T-AOC, A), serum superoxide dismutase (Serum SOD, B), malondialdehyde (Serum MDA, C), bone marrow total antioxidant capacity (BM-T-AOC, D) and bone marrow superoxide dismutase (BM-SOD, E). The primary BMSCs (F) was characterized by flow cytometry (G). Effects of lycopene on BMSCs proliferation with/without H2O2 exposure after 24, 48 and 72 h (H- J) were determined by a CCK-8 assay. The intracellular levels of ROS were determined by the DCFH-DA (K). SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, EV denotes the estradiol group, LYCH denotes the high-dose lycopene group, LYCL denotes the low-dose lycopene group. CON denotes the blank control, H2O2 denotes the stimulation of H2O2 for 1 h, LYC2 denotes the 2 μM of lycopene treatment, LYC4 denotes 4 μM of lycopene treatment. # vs the SHAM or CON group, * vs the OVX or H2O2 group. p < 0.05 was considered statistically significant.
Figure 2. Lycopene inhibits oxidative stress in OVX rats and in BMSCs. Serum and bone marrow levels of oxidative stress markers were determined by biochemical assays, including serum total antioxidant capacity (Serum T-AOC, A), serum superoxide dismutase (Serum SOD, B), malondialdehyde (Serum MDA, C), bone marrow total antioxidant capacity (BM-T-AOC, D) and bone marrow superoxide dismutase (BM-SOD, E). The primary BMSCs (F) was characterized by flow cytometry (G). Effects of lycopene on BMSCs proliferation with/without H2O2 exposure after 24, 48 and 72 h (H- J) were determined by a CCK-8 assay. The intracellular levels of ROS were determined by the DCFH-DA (K). SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, EV denotes the estradiol group, LYCH denotes the high-dose lycopene group, LYCL denotes the low-dose lycopene group. CON denotes the blank control, H2O2 denotes the stimulation of H2O2 for 1 h, LYC2 denotes the 2 μM of lycopene treatment, LYC4 denotes 4 μM of lycopene treatment. # vs the SHAM or CON group, * vs the OVX or H2O2 group. p < 0.05 was considered statistically significant.
Preprints 102987 g002
Preprints 102987 g003
Figure 3. Lycopene improves lipid metabolism in OVX rats and in BMSCs. Body weight (A), serum triglycerides (Serum TG, B), serum total cholesterol (Serum TC, C), serum low-density lipoprotein (Serum LDL, D), serum high-density lipoprotein (Serum HDL, E), bone marrow TG (BM-TG, F) and bone marrow TC (BM-TC, G). Oil Red O staining and its analysis in BMSCs (I, H). SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, EV denotes the estradiol group, LYCH denotes the high-dose lycopene group, LYCL denotes the low-dose lycopene group. CON denotes the blank control, H2O2 denotes the stimulation of H2O2 for 1 h, LYC2 denotes 2 μM of lycopene treatment, LYC4 denotes 4 μM of lycopene treatment. # vs the SHAM or CON group, * vs the OVX or H2O2 group. p < 0.05 was considered statistically significant.
Figure 3. Lycopene improves lipid metabolism in OVX rats and in BMSCs. Body weight (A), serum triglycerides (Serum TG, B), serum total cholesterol (Serum TC, C), serum low-density lipoprotein (Serum LDL, D), serum high-density lipoprotein (Serum HDL, E), bone marrow TG (BM-TG, F) and bone marrow TC (BM-TC, G). Oil Red O staining and its analysis in BMSCs (I, H). SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, EV denotes the estradiol group, LYCH denotes the high-dose lycopene group, LYCL denotes the low-dose lycopene group. CON denotes the blank control, H2O2 denotes the stimulation of H2O2 for 1 h, LYC2 denotes 2 μM of lycopene treatment, LYC4 denotes 4 μM of lycopene treatment. # vs the SHAM or CON group, * vs the OVX or H2O2 group. p < 0.05 was considered statistically significant.
Preprints 102987 g003
Preprints 102987 g004
Figure 4. Lycopene promotes osteogenesis in OVX rats and in BMSCs. Serum levels of PINP (A) and CTX-I (B). (C&D) The representative images of Safranin O/fast green staining and their analyses show the GAG levels in the femurs. The representative images of alizarin red S staining and their analyses show the osteogenesis and calcium nodules in the different groups of rats (E&F) and BMSCs (G&H). Blue star denotes calcium nodules (E). SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, EV denotes the estradiol group, LYCH denotes the high-dose lycopene group, LYCL denotes the low-dose lycopene group. CON denotes the blank control, H2O2 denotes the stimulation of H2O2 for 1 h, LYC2 denotes 2 μM of lycopene treatment, LYC4 denotes 4 μM of lycopene treatment. # vs the SHAM or CON group, * vs the OVX or H2O2 group. p < 0.05 was considered statistically significant.
Figure 4. Lycopene promotes osteogenesis in OVX rats and in BMSCs. Serum levels of PINP (A) and CTX-I (B). (C&D) The representative images of Safranin O/fast green staining and their analyses show the GAG levels in the femurs. The representative images of alizarin red S staining and their analyses show the osteogenesis and calcium nodules in the different groups of rats (E&F) and BMSCs (G&H). Blue star denotes calcium nodules (E). SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, EV denotes the estradiol group, LYCH denotes the high-dose lycopene group, LYCL denotes the low-dose lycopene group. CON denotes the blank control, H2O2 denotes the stimulation of H2O2 for 1 h, LYC2 denotes 2 μM of lycopene treatment, LYC4 denotes 4 μM of lycopene treatment. # vs the SHAM or CON group, * vs the OVX or H2O2 group. p < 0.05 was considered statistically significant.
Preprints 102987 g004
Preprints 102987 g005
Figure 5. Lycopene increases FoxO1, Runx2, and OCN expressions, and inhibits PPARγ and C/EBPα expressions in the femurs and tibias of OVX rats and in BMSCs. The expressions of FoxO1, PPARγ, Runx2, OCN and C/EBPα in the femurs and tibias were determined by immunohistochemical staining (A, B, D, E, G, H, J and K) and western blot (C, F, I and L). The expressions of FoxO1, Runx2 and PPARγ in BMSCs were determined by western blot (M, N and O). SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, LYCL denotes the low dose lycopene group. CON denotes the blank control, H2O2 denotes the stimulation of H2O2 for 1 h, LYC2 denotes 2 μM of lycopene treatment, AS1842856 denotes FoxO1 inhibitor, AS1842856+LYC2 denotes the co-treatment of FoxO1 inhibitor and 2 μM of lycopene. # vs the SHAM or CON group, * vs the OVX or H2O2 group. p < 0.05 was considered statistically significant.
Figure 5. Lycopene increases FoxO1, Runx2, and OCN expressions, and inhibits PPARγ and C/EBPα expressions in the femurs and tibias of OVX rats and in BMSCs. The expressions of FoxO1, PPARγ, Runx2, OCN and C/EBPα in the femurs and tibias were determined by immunohistochemical staining (A, B, D, E, G, H, J and K) and western blot (C, F, I and L). The expressions of FoxO1, Runx2 and PPARγ in BMSCs were determined by western blot (M, N and O). SHAM denotes the sham operation group, OVX denotes the ovariectomized model group, LYCL denotes the low dose lycopene group. CON denotes the blank control, H2O2 denotes the stimulation of H2O2 for 1 h, LYC2 denotes 2 μM of lycopene treatment, AS1842856 denotes FoxO1 inhibitor, AS1842856+LYC2 denotes the co-treatment of FoxO1 inhibitor and 2 μM of lycopene. # vs the SHAM or CON group, * vs the OVX or H2O2 group. p < 0.05 was considered statistically significant.
Preprints 102987 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Alerts
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2025 MDPI (Basel, Switzerland) unless otherwise stated